Cocrystal Pharma

COCP · NASDAQ

$0.9429−$0.0037 (−0.39%)TodayMarket closed ·
Prev close $0.9466

Latest news

  • Press releaseGlobe Newswire

    Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment

  • Press releaseGlobe Newswire

    Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors

  • Press releaseGlobe Newswire

    Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health

  • Press releaseGlobe Newswire

    Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer

  • News

    Watching Cocrystal Pharma; Zacks-Small Cap Research Gives Stock $8 Price Valuation

  • Press releaseGlobe Newswire

    Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza

  • Press releaseGlobe Newswire

    Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results

  • Press releaseGlobe Newswire

    Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection

  • NewsKaustubh Bagalkote

    Why Cocrystal Pharma Shares Are Cooling Off Monday?

  • News

    12 Health Care Stocks Moving In Monday's Pre-Market Session

  • NewsAvi Kapoor

    Crude Oil Rises Sharply; Acuity Shares Fall After Q2 Results

  • News

    12 Health Care Stocks Moving In Thursday's Intraday Session

  • NewsAvi Kapoor

    Nasdaq Down 1%; US Initial Jobless Claims Fall

  • NewsDylan Berman

    Cocrystal Pharma Shares Soar After FDA Grants Fast Track Status To CDI-988

  • News

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • News

    Cocrystal Pharma Says FDA Grants Fast Track Designation To Its Direct-Acting Protease Inhibitor, CDI-988, Oral Antiviral Candidate Being Developed For Treatment And Prophylaxis Of Norovirus Infection

  • Press releaseGlobe Newswire

    Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive

  • News

    12 Health Care Stocks Moving In Thursday's After-Market Session

  • Press releaseGlobe Newswire

    Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

  • NewsAvi Kapoor

    Dow Dips Over 100 Points; Cocrystal Pharma Shares Slide

  • NewsAvi Kapoor

    Crude Oil Rises 1%; Sangamo Therapeutics Shares Plummet

  • NewsAvi Kapoor

    US Stocks Open Higher; House Prices Increase In October

  • News

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • News

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • News

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • NewsAvi Kapoor

    Toll Brothers To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.